Hospira (NYSE: HSP ) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hospira's revenues will grow 1.8% and EPS will decrease -6.4%.
The average estimate for revenue is $982.9 million. On the bottom line, the average EPS estimate is $0.44.
Last quarter, Hospira recorded revenue of $1.10 billion. GAAP reported sales were 8.4% higher than the prior-year quarter's $1.01 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.55. GAAP EPS were $0.03 for Q4 compared to -$1.30 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 30.0%, 200 basis points better than the prior-year quarter. Operating margin was 6.2%, 130 basis points better than the prior-year quarter. Net margin was 0.5%, much better than the prior-year quarter.
The full year's average estimate for revenue is $4.11 billion. The average EPS estimate is $2.03.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 132 members out of 160 rating the stock outperform, and 28 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Hospira a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $33.14.
- Add Hospira to My Watchlist.